₹171
▲ +4.01 +2.40%
As of 26 Oct 2026 · delayed
BSE Listed
Mahamaya Lifesciences Limited (544611)
Volume: 1,200Avg Vol 1W: 12,000Avg Vol 1M: 27,00052W Range:₹111₹205.05
Key Ratios
Checked 9h agoMarket Cap₹400 Cr
Current Price₹171
Previous Close₹166.99
High / Low (52w)₹205.05 / ₹111
Volume1,200
Avg Vol (1W)12,000
Avg Vol (1M)27,000
Stock P/E24.22
Book Value₹52.1
Dividend Yield0%
ROE13.55%
ROA286.7%
Revenue (TTM)—
Revenue Growth—
Profit Margin457.94%
Total Debt—
Shares Outstanding2 Cr
Face Value—
EPS (TTM)₹7.06
P/B3.28
Debt / Equity0.87
50 DMA₹181.82
200 DMA₹174.77
Day change+2.40%
Price Chart
₹171▲ 48.70% · 1Y
2025-11-182026-10-26
20-day avg volume: 24K shares
Pros
- Company is almost debt-free.
- Revenue grew 24% YoY.
- Net profit is growing year over year.
Profit & Loss (Annual)
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | ₹90 Cr | ₹137 Cr | ₹163 Cr | ₹267 Cr | ₹330 Cr |
| EBITDA | ₹5 Cr | ₹8 Cr | ₹13 Cr | ₹24 Cr | ₹32 Cr |
| Net Profit | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹13 Cr | ₹17 Cr |
| EPS | 21.81 | 30.03 | 41.79 | 7.52 | 8.33 |
Balance Sheet
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | ₹56 Cr | ₹78 Cr | ₹112 Cr | ₹188 Cr | ₹310 Cr |
| Total Liabilities | ₹40 Cr | ₹58 Cr | ₹87 Cr | ₹139 Cr | ₹188 Cr |
| Equity | ₹16 Cr | ₹19 Cr | ₹25 Cr | ₹49 Cr | ₹122 Cr |
| Total Debt | — | — | — | — | — |
Cash Flow
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | ₹3 Cr | ₹2 Cr | ₹-21 Cr | ₹1 Cr | ₹-25 Cr |
| Investing | ₹-3 Cr | ₹-3 Cr | ₹-2 Cr | ₹-7 Cr | ₹-16 Cr |
| Financing | ₹1 Cr | ₹2 Cr | ₹24 Cr | ₹9 Cr | ₹81 Cr |
| Free Cash Flow | ₹3 Cr | ₹2 Cr | ₹-21 Cr | ₹1 Cr | ₹-25 Cr |
Shareholding
Promoter 56.39% Institutions 4.67% Public 38.94%
Efficiency & Working Capital
ROCE15.1%
Interest Coverage3.9
Dividend Payout—
Debtor Days78 d
Inventory Days156 d
Payable Days71 d
Cash Conversion Cycle163 d
Working Capital Days235 d
Shareholding Details
As of 2026-09-30
Promoter56.4%
FII2.7%
DII2%
Institutions4.7%
Public38.9%
Promoter Pledge0%
No. of Shareholders691
Shareholding Pattern
Quarterly — figures in %. Latest 5 quarters.
| Period | Feb 2025 | Oct 2025 | Nov 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|
| Promoters | 77.3% | 77.3% | 56.3% | 56.3% | 56.4% |
| FIIs | 0% | 0% | 6.4% | 4.8% | 2.7% |
| DIIs | 0% | 0% | 4.7% | 2.5% | 2% |
| Public | 22.7% | 22.7% | 32.6% | 36.4% | 38.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 18 | 18 | 1,034 | 584 | 691 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Krishnamurthy Ganesan | Shareholding of Promoter and Promoter Group | 21.9% | 51,16,250 |
| Prashant Krishnamurthy | Shareholding of Promoter and Promoter Group | 17.7% | 41,30,475 |
| Lalitha Krishnamurthy | Shareholding of Promoter and Promoter Group | 16.9% | 39,50,875 |
| Pink Tiger Alliances Llp | Public Shareholding | 10.4% | 24,22,200 |
| Kedia Securities Private Limited | Public Shareholding | 4.5% | 10,60,800 |
| Sanjay Popatlal Jain | Public Shareholding | 4.1% | 9,52,800 |
| Minerva Ventures Fund | Public Shareholding | 2.3% | 5,34,000 |
| Nav Capital Vcc - Nav Capital Emerging Star Fund | Public Shareholding | 1.7% | 4,04,400 |
| Suresh Bhatia Huf | Public Shareholding | 1.4% | 3,30,000 |
| Multiplier Share & Stock Advisors Pvt Ltd | Public Shareholding | 1.3% | 3,00,000 |
| Nikhil K S | Public Shareholding | 1.1% | 2,65,200 |
| Kifs Trade Capital Private Limited | Public Shareholding | 1.1% | 2,53,200 |
| Navbharat Investment Trust-navbharat Investment Op | Public Shareholding | 1% | 2,41,200 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| PRASHANT KRISHNAMURTHY | Executive Director & CFO | 2025 |
| Krishnamurthy Ganesan | Managing Director | 2025 |
| Lalitha Krishnamurthy | Whole-time Director | 2025 |
| CHARUDATTA DIGAMBAR MAYEE | Independent Non Exe. Director | 2025 |
| Gopal Krishna Raju | Independent Non Exe. Director | 2025 |
| SEKHAR KAVASSERI RAJAGOPALAN | Independent Non Exe. Director | 2025 |
| Bhagirath Choudhary | Additional Director | 2025 |
| Kush Mishra | Company Secretary / Compliance Officer | 2025 |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹10 | 25 | 23 | 23 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 4 | 1 | 5 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 1 |
| 2025 | 0 | 0 | 0 | 3 | 1 | 4 |
Insider / Designated-Person Trades
2 recent disclosure(s)
PRASHANT KRISHNAMURTHYAcquisition · 2,400
PRASHANT KRISHNAMURTHYAcquisition · 4,800
Company Information
🌐 www.mahamayalifesciences.com ↗
📍 #DPT-033 Gr Flr Plt #79-80 DLF, Prime Tower F Blo.Okhla Phase1, New Delhi, New Delhi, 110020
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search